MADRIGAL PHARMACEUTICALS, INC. Other Noncash Income (Expense)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Other Noncash Income (Expense) of $2.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was $65.00K.
- MADRIGAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was $2.44M.
- MADRIGAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was $330.00K.
- MADRIGAL PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-06-30 was -$942.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month |
|---|---|---|---|
| 2026-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.50M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $2.44M 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | $330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$612.00K derived: sum of 2 quarters · filed 2026-07-30 | -$612.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$942.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$942.00K 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |